WO2001014415A3 - Gènes egfh2 et produits géniques - Google Patents

Gènes egfh2 et produits géniques Download PDF

Info

Publication number
WO2001014415A3
WO2001014415A3 PCT/US2000/022326 US0022326W WO0114415A3 WO 2001014415 A3 WO2001014415 A3 WO 2001014415A3 US 0022326 W US0022326 W US 0022326W WO 0114415 A3 WO0114415 A3 WO 0114415A3
Authority
WO
WIPO (PCT)
Prior art keywords
egfh2
genes
gene products
relates
polynucleotides
Prior art date
Application number
PCT/US2000/022326
Other languages
English (en)
Other versions
WO2001014415A2 (fr
Inventor
W Michael Kavanaugh
Hui Cen
Pauline Lee
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to JP2001518744A priority Critical patent/JP2003510029A/ja
Priority to EP00955542A priority patent/EP1208198A2/fr
Priority to AU67732/00A priority patent/AU6773200A/en
Publication of WO2001014415A2 publication Critical patent/WO2001014415A2/fr
Publication of WO2001014415A3 publication Critical patent/WO2001014415A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)

Abstract

L'invention concerne un EGFH2 murin et humain ainsi que ses variantes et des polynucléotides codant pour EGFH2. L'invention concerne également des agents thérapeutiques correspondant à ces polynucléotides et à ces protéines.
PCT/US2000/022326 1999-08-20 2000-08-15 Gènes egfh2 et produits géniques WO2001014415A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001518744A JP2003510029A (ja) 1999-08-20 2000-08-15 Ｅｇｆｈ２遺伝子および遺伝子産物
EP00955542A EP1208198A2 (fr) 1999-08-20 2000-08-15 G nes egfh2 et produits g niques
AU67732/00A AU6773200A (en) 1999-08-20 2000-08-15 Egfh2 genes and gene products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14998699P 1999-08-20 1999-08-20
US60/149,986 1999-08-20

Publications (2)

Publication Number Publication Date
WO2001014415A2 WO2001014415A2 (fr) 2001-03-01
WO2001014415A3 true WO2001014415A3 (fr) 2001-07-26

Family

ID=22532642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/022326 WO2001014415A2 (fr) 1999-08-20 2000-08-15 Gènes egfh2 et produits géniques

Country Status (4)

Country Link
EP (1) EP1208198A2 (fr)
JP (1) JP2003510029A (fr)
AU (1) AU6773200A (fr)
WO (1) WO2001014415A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
US6544759B1 (en) 2000-04-21 2003-04-08 Yeda Research And Development Co. Ltd Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
AU2003237367A1 (en) 2002-06-03 2003-12-19 Chiron Corporation Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
ES2751391T3 (es) * 2013-03-21 2020-03-31 Univ Michigan Regents Procedimientos de tratamiento de trastornos metabólicos
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002681A1 (fr) * 1997-07-09 1999-01-21 Genentech, Inc. Neureguline specifique au recepteur de erbb4, ligands associes et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002681A1 (fr) * 1997-07-09 1999-01-21 Genentech, Inc. Neureguline specifique au recepteur de erbb4, ligands associes et leurs utilisations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GARRAWAY K L ET AL: "Neuregulin-2, a new ligand of Erb3/Erb4-receptor tyrosine kinase", NATURE,GB,MACMILLAN JOURNALS LTD. LONDON, no. 387, 29 May 1997 (1997-05-29), pages 512 - 516, XP002080140, ISSN: 0028-0836 *
HARARI D ET AL: "Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.", ONCOGENE, vol. 18, no. 17, 29 April 1999 (1999-04-29), pages 2681 - 2689, XP000097546, ISSN: 0950-9232 *
ZHANG D X ET AL: "Neuregulin-3: a novel neural tissue-enriched protein that binds and activates ErbB4", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, no. 94, 1 September 1997 (1997-09-01), pages 9562 - 9567, XP002080141, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU6773200A (en) 2001-03-19
WO2001014415A2 (fr) 2001-03-01
EP1208198A2 (fr) 2002-05-29
JP2003510029A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
WO1999033982A3 (fr) Genes humains et produits d'expression genique i
WO1999038972A3 (fr) Genes humains et produits ii d'expression genique
WO1999058675A3 (fr) Genes humains et produits d'expression genique v
WO2002014500A3 (fr) Genes humains et produits d'expression genique
WO2001066753A3 (fr) Nouveaux genes humains et leurs produits d'expression
WO1998059040A3 (fr) Sous-unite de telomerase catalytique humaine et son utilisation therapeutique et diagnostique
ZA200109348B (en) Noninvasive genetic immunization, expression products therefrom, and uses thereof.
AU5305000A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO1998033937A3 (fr) SEQUENCE GENOMIQUE DU GENE RECEPTEUR ν-OPIOIDE HUMAIN, AINSI QUE SES VARIANTES, POLYMORPHISMES ET MUTATIONS
WO2001014415A3 (fr) Gènes egfh2 et produits géniques
EP0979309A4 (fr) Oligonucleotides presentant une meilleure biodisponibilite
WO2000018916A3 (fr) Genes humains et produits d'expression genique
GB2349150B (en) Expression of DNA or proteins in C. Elegans
WO2001072781A3 (fr) Genes humains et produits d'expression genique xvi
AU5619700A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
EP1329504A4 (fr) Acide nucleique d'un nouveau gene humain associe a la kinesine, proteine codees par cet acide nucleique, fragment de peptide de cet acide nucleique et agents anticancereux comprenant cet acide nucleique et similaire
MXPA01012500A (es) Productos para terapia de gen.
WO2002070563A3 (fr) Domaine de liaison de ligand au recepteur hormonal nucleaire
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
WO1999046381A3 (fr) Gene du fgf humain et produit d'expression genique
ATE221895T1 (de) Chimäre oligonucleotide und ihre verwendung
WO2002070562A3 (fr) Domaine de liaison du ligand du recepteur hormonal nucleaire
WO2002034901A8 (fr) Proteine kinase
AU5904400A (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002046380A3 (fr) Proteine kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000955542

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000955542

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642